Literature DB >> 32365196

Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.

Raffaele Coppini1, Lorenzo Santini1, Iacopo Olivotto2,3, Michael J Ackerman4,5,6, Elisabetta Cerbai1,7.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a common inherited monogenic disease with a prevalence of 1/500 in the general population, representing an important cause of arrhythmic sudden cardiac death (SCD), heart failure, and atrial fibrillation in the young. HCM is a global condition, diagnosed in >50 countries and in all continents. HCM affects people of both sexes and various ethnic and racial origins, with similar clinical course and phenotypic expression. The most unpredictable and devastating consequence of HCM is represented by arrhythmic SCD, most commonly caused by sustained ventricular tachycardia or ventricular fibrillation. Indeed, HCM represents one of the main causes of arrhythmic SCD in the young, with a marked preference for children and adults <30 years. SCD is most prevalent in patients with paediatric onset of HCM but may occur at any age. However, risk is substantially lower after 60 years, suggesting that the potential for ventricular tachyarrhythmias is mitigated by ageing. SCD had been linked originally to sports and vigorous activity in HCM patients. However, it is increasingly clear that the majority of events occurs at rest or during routine daily occupations, suggesting that triggers are far from consistent. In general, the pathophysiology of SCD in HCM remains unresolved. While the pathologic and physiologic substrates abound and have been described in detail, specific factors precipitating ventricular tachyarrhythmias are still unknown. SCD is a rare phenomenon in HCM cohorts (<1%/year) and attempts to identify patients at risk, while generating clinically useful algorithms for primary prevention, remain very inaccurate on an individual basis. One of the reasons for our limited understanding of these phenomena is that limited translational research exists in the field, while most efforts have focused on clinical markers of risk derived from pathology, instrumental patient evaluation, and imaging. Specifically, few studies conducted in animal models and human samples have focused on targeting the cellular mechanisms of arrhythmogenesis in HCM, despite potential implications for therapeutic innovation and SCD prevention. These studies found that altered intracellular Ca2+ homoeostasis and increased late Na+ current, leading to an increased likelihood of early and delayed after-depolarizations, contribute to generate arrhythmic events in diseased cardiomyocytes. As an array of novel experimental opportunities have emerged to investigate these mechanisms, including novel 'disease-in-the-dish' cellular models with patient-specific induced pluripotent stem cell-derived cardiomyocytes, important gaps in knowledge remain. Accordingly, the aim of the present review is to provide a contemporary reappraisal of the cellular basis of SCD-predisposing arrhythmias in patients with HCM and discuss the implications for risk stratification and management. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ranolazine; Action potential; Afterdepolarizations; Cardiomyocytes; Channelopathies; Excitation–contraction coupling; HCM; Ion channels

Year:  2020        PMID: 32365196     DOI: 10.1093/cvr/cvaa124

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

Review 1.  Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

Authors:  Chiara Palandri; Lorenzo Santini; Alessia Argirò; Francesca Margara; Ruben Doste; Alfonso Bueno-Orovio; Iacopo Olivotto; Raffaele Coppini
Journal:  Drugs       Date:  2022-06-13       Impact factor: 11.431

2.  Mexiletine-like cellular electrophysiological effects of GS967 in canine ventricular myocardium.

Authors:  Tamás Hézső; Muhammad Naveed; Csaba Dienes; Dénes Kiss; János Prorok; Tamás Árpádffy-Lovas; Richárd Varga; Erika Fujii; Tanju Mercan; Leila Topal; Kornél Kistamás; Norbert Szentandrássy; János Almássy; Norbert Jost; János Magyar; Tamás Bányász; István Baczkó; András Varró; Péter P Nánási; László Virág; Balázs Horváth
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

3.  Inherited conditions of arrhythmia: translating disease mechanisms to patient management.

Authors:  Silvia G Priori; Carol Ann Remme
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

4.  Identification of cardiomyopathy-related core genes through human metabolic networks and expression data.

Authors:  Zherou Rong; Hongwei Chen; Zihan Zhang; Yue Zhang; Luanfeng Ge; Zhengyu Lv; Yuqing Zou; Junjie Lv; Yuehan He; Wan Li; Lina Chen
Journal:  BMC Genomics       Date:  2022-01-12       Impact factor: 3.969

5.  Cardiomyocyte Na+ and Ca2+ mishandling drives vicious cycle involving CaMKII, ROS, and ryanodine receptors.

Authors:  Bence Hegyi; Risto-Pekka Pölönen; Kim T Hellgren; Christopher Y Ko; Kenneth S Ginsburg; Julie Bossuyt; Mark Mercola; Donald M Bers
Journal:  Basic Res Cardiol       Date:  2021-10-14       Impact factor: 17.165

Review 6.  Cytoskeletal Protein Variants Driving Atrial Fibrillation: Potential Mechanisms of Action.

Authors:  Stan W van Wijk; Wei Su; Leonoor F J M Wijdeveld; Kennedy S Ramos; Bianca J J M Brundel
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

7.  Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy-An Analysis from the SILICOFCM Database.

Authors:  Andrej Preveden; Miodrag Golubovic; Marija Bjelobrk; Tatjana Miljkovic; Aleksandra Ilic; Snezana Stojsic; Dragan Gajic; Mila Glavaski; Lars S Maier; Nduka Okwose; Dejana Popovic; Fausto Barlocco; Arsen Ristic; Guy A MacGowan; Iacopo Olivotto; Nenad Filipovic; Djordje G Jakovljevic; Lazar Velicki
Journal:  Medicina (Kaunas)       Date:  2022-02-18       Impact factor: 2.430

Review 8.  Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside.

Authors:  Hua Shen; Shi-Yong Dong; Ming-Shi Ren; Rong Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-18

9.  Whole-exome sequencing reveals MYH7 p.R671C mutation in three different phenotypes of familial hypertrophic cardiomyopathy.

Authors:  Wei Yu; Mi-Mi Huang; Guo-Hong Zhang; Wei Wang; Chun-Juan Chen; Ji-Dong Cheng
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.